Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Bicycle Therapeutics to related businesses based on the strength of its profitability, risk, analyst recommendations, dividends, institutional ownership, valuation and earnings.
Profitability
This table compares Bicycle Therapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bicycle Therapeutics | -169.75% | -26.02% | -22.30% |
| Bicycle Therapeutics Competitors | -12,224.75% | -204.85% | -31.52% |
Risk and Volatility
Bicycle Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics’ rivals have a beta of -1.85, meaning that their average stock price is 285% less volatile than the S&P 500.
Valuation & Earnings
This table compares Bicycle Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Bicycle Therapeutics | $72.86 million | -$218.96 million | -1.43 |
| Bicycle Therapeutics Competitors | $688.58 million | $7.69 million | -17.98 |
Bicycle Therapeutics’ rivals have higher revenue and earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 22.0% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Bicycle Therapeutics and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bicycle Therapeutics | 1 | 4 | 5 | 0 | 2.40 |
| Bicycle Therapeutics Competitors | 9945 | 15356 | 45765 | 1601 | 2.54 |
Bicycle Therapeutics presently has a consensus price target of $13.57, indicating a potential upside of 368.79%. As a group, “Biotechnology” companies have a potential upside of 114.65%. Given Bicycle Therapeutics’ higher probable upside, equities analysts clearly believe Bicycle Therapeutics is more favorable than its rivals.
Summary
Bicycle Therapeutics beats its rivals on 7 of the 12 factors compared.
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a focus on cancer. Founded in 2009, the company grew out of research at the University of Cambridge in the United Kingdom and has operations in Cambridge, UK, and Cambridge, Massachusetts. The company’s proprietary Bicycle platform creates small, constrained peptides that can bind to specific biological targets. Bicycle Therapeutics is using this technology to develop treatments that may be designed to reach targets that are difficult for conventional drugs to access.
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
